My Cart [ 0 ]
Home > Antibodies > Research-Grade Biosimilars > Matuzumab Biosimilar, EGFR Monoclonal Antibody

Matuzumab Biosimilar, EGFR Monoclonal Antibody

epidermal growth factor receptor, EGF receptor

Catalog No. Product Name Size List Price (US$) Quantity
C051P Matuzumab Biosimilar, EGFR Monoclonal Antibody 1 mg 250.00
C051P Matuzumab Biosimilar, EGFR Monoclonal Antibody 5 mg 750.00
C051P Matuzumab Biosimilar, EGFR Monoclonal Antibody 20 mg 2500.00
Description

C051P: Matuzumab Biosimilar, EGFR Monoclonal Antibody

Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype: Human IgG1 kappa.
Source: The anti-human EGFR monoclonal antibody matuzumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity: The research grade matuzumab biosimilar specifically binds to the human epidermal growth factor receptor (EGFR).
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by matuzumab.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The research grade matuzumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Background

Matuzumab Biosimilar uses the same protein sequences as the therapeutic antibody matuzumab.

Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR (epithelial growth factor receptor), frequently associated with the growth of blood vessels in malignancy, facilitating tumor growth and survival.

Matuzumab binds the epidermal growth factor receptor (EGFR) with high affinity, competitively blocking natural ligand binding and blocking receptor-mediated downstream signalling, resulting in impaired tumor cell proliferation. Matuzumab (EMD-72000) is a humanized IgG1 MAb that not only binds with high specificity and affinity to EGFR, but also modulates antibody-dependent cellular cytotoxicity (ADCC).

Related Links

See our Privacy Policy